These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 35456261)

  • 1. Neurofibromatosis Type 1 Has a Wide Spectrum of Growth Hormone Excess.
    Hannah-Shmouni F; Trivellin G; Beckers P; Karaviti LP; Lodish M; Tatsi C; Adesina AM; Adamidou F; Mintziori G; Josefson JL; Quezado M; Stratakis CA
    J Clin Med; 2022 Apr; 11(8):. PubMed ID: 35456261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone excess in children with neurofibromatosis type-1 and optic glioma.
    Cambiaso P; Galassi S; Palmiero M; Mastronuzzi A; Del Bufalo F; Capolino R; Cacchione A; Buonuomo PS; Gonfiantini MV; Bartuli A; Cappa M; Macchiaiolo M
    Am J Med Genet A; 2017 Sep; 173(9):2353-2358. PubMed ID: 28631895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acromegaly caused by a somatotroph adenoma in patient with neurofibromatosis type 1.
    Hozumi K; Fukuoka H; Odake Y; Takeuchi T; Uehara T; Sato T; Inoshita N; Yoshida K; Matsumoto R; Bando H; Hirota Y; Iguchi G; Taniguchi M; Otsuki N; Nishigori C; Kosaki K; Hasegawa T; Ogawa W; Takahashi Y
    Endocr J; 2019 Oct; 66(10):853-857. PubMed ID: 31189769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study.
    Iacovazzo D; Caswell R; Bunce B; Jose S; Yuan B; Hernández-Ramírez LC; Kapur S; Caimari F; Evanson J; Ferraù F; Dang MN; Gabrovska P; Larkin SJ; Ansorge O; Rodd C; Vance ML; Ramírez-Renteria C; Mercado M; Goldstone AP; Buchfelder M; Burren CP; Gurlek A; Dutta P; Choong CS; Cheetham T; Trivellin G; Stratakis CA; Lopes MB; Grossman AB; Trouillas J; Lupski JR; Ellard S; Sampson JR; Roncaroli F; Korbonits M
    Acta Neuropathol Commun; 2016 Jun; 4(1):56. PubMed ID: 27245663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GHRH excess and blockade in X-LAG syndrome.
    Daly AF; Lysy PA; Desfilles C; Rostomyan L; Mohamed A; Caberg JH; Raverot V; Castermans E; Marbaix E; Maiter D; Brunelle C; Trivellin G; Stratakis CA; Bours V; Raftopoulos C; Beauloye V; Barlier A; Beckers A
    Endocr Relat Cancer; 2016 Mar; 23(3):161-70. PubMed ID: 26671997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Genetic Pathophysiology and Clinical Management of the TADopathy, X-Linked Acrogigantism.
    Daly AF; Beckers A
    Endocr Rev; 2024 Sep; 45(5):737-754. PubMed ID: 38696651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gigantism: X-linked acrogigantism and GPR101 mutations.
    Iacovazzo D; Korbonits M
    Growth Horm IGF Res; 2016; 30-31():64-69. PubMed ID: 27743704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of G
    Abboud D; Daly AF; Dupuis N; Bahri MA; Inoue A; Chevigné A; Ectors F; Plenevaux A; Pirotte B; Beckers A; Hanson J
    Nat Commun; 2020 Sep; 11(1):4752. PubMed ID: 32958754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversible Growth Hormone Excess in Two Girls with Neurofibromatosis Type 1 and Optic Pathway Glioma.
    Bruzzi P; Sani I; Albanese A
    Horm Res Paediatr; 2015; 84(6):414-22. PubMed ID: 26488470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a Brief Review of the Literature.
    Friedrich RE; Nuding MA
    Anticancer Res; 2016 Aug; 36(8):4095-121. PubMed ID: 27466519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GPR101 Mutations are not a Frequent Cause of Congenital Isolated Growth Hormone Deficiency.
    Castinetti F; Daly AF; Stratakis CA; Caberg JH; Castermans E; Trivellin G; Rostomyan L; Saveanu A; Jullien N; Reynaud R; Barlier A; Bours V; Brue T; Beckers A
    Horm Metab Res; 2016 Jun; 48(6):389-93. PubMed ID: 26797872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optic pathway glioma and the sex association in neurofibromatosis type 1: a single-center study.
    Henning AM; Handrup MM; Kjeldsen SM; Larsen DA; Ejerskov C
    Orphanet J Rare Dis; 2021 Nov; 16(1):489. PubMed ID: 34809690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gigantism due to growth hormone excess in a boy with optic glioma.
    Drimmie FM; MacLennan AC; Nicoll JA; Simpson E; McNeill E; Donaldson MD
    Clin Endocrinol (Oxf); 2000 Oct; 53(4):535-8. PubMed ID: 11012581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An orphan G-protein-coupled receptor causes human gigantism and/or acromegaly: Molecular biology and clinical correlations.
    Trivellin G; Hernández-Ramírez LC; Swan J; Stratakis CA
    Best Pract Res Clin Endocrinol Metab; 2018 Apr; 32(2):125-140. PubMed ID: 29678281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optic Pathway Glioma in Children with Neurofibromatosis Type 1: A Multidisciplinary Entity, Posing Dilemmas in Diagnosis and Management Multidisciplinary Management of Optic Pathway Glioma in Children with Neurofibromatosis Type 1.
    Lohkamp LN; Parkin P; Puran A; Bartels UK; Bouffet E; Tabori U; Rutka JT
    Front Surg; 2022; 9():886697. PubMed ID: 35592129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duplications disrupt chromatin architecture and rewire GPR101-enhancer communication in X-linked acrogigantism.
    Franke M; Daly AF; Palmeira L; Tirosh A; Stigliano A; Trifan E; Faucz FR; Abboud D; Petrossians P; Tena JJ; Vitali E; Lania AG; Gómez-Skarmeta JL; Beckers A; Stratakis CA; Trivellin G
    Am J Hum Genet; 2022 Apr; 109(4):553-570. PubMed ID: 35202564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation.
    Trivellin G; Daly AF; Faucz FR; Yuan B; Rostomyan L; Larco DO; Schernthaner-Reiter MH; Szarek E; Leal LF; Caberg JH; Castermans E; Villa C; Dimopoulos A; Chittiboina P; Xekouki P; Shah N; Metzger D; Lysy PA; Ferrante E; Strebkova N; Mazerkina N; Zatelli MC; Lodish M; Horvath A; de Alexandre RB; Manning AD; Levy I; Keil MF; Sierra Mde L; Palmeira L; Coppieters W; Georges M; Naves LA; Jamar M; Bours V; Wu TJ; Choong CS; Bertherat J; Chanson P; Kamenický P; Farrell WE; Barlier A; Quezado M; Bjelobaba I; Stojilkovic SS; Wess J; Costanzi S; Liu P; Lupski JR; Beckers A; Stratakis CA
    N Engl J Med; 2014 Dec; 371(25):2363-74. PubMed ID: 25470569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case report: Management of pediatric gigantism caused by the TADopathy, X-linked acrogigantism.
    Caruso M; Mazzatenta D; Asioli S; Costanza G; Trivellin G; Franke M; Abboud D; Hanson J; Raverot V; Pétrossians P; Beckers A; Cappa M; Daly AF
    Front Endocrinol (Lausanne); 2024; 15():1345363. PubMed ID: 38481440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth Hormone Excess in Children with Optic Pathway Tumors Is a Transient Phenomenon.
    Josefson JL; Listernick R; Charrow J; Habiby RL
    Horm Res Paediatr; 2016; 86(1):35-8. PubMed ID: 27348432
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.